
### [NCIT:C8518](http://purl.obolibrary.org/obo/NCIT_C8518)
**Label:** Stage II Hodgkin Lymphoma

**Subclasses:** [NCIT:C5070](http://purl.obolibrary.org/obo/NCIT_C5070) (Stage II Nodular Lymphocyte Predominant Hodgkin Lymphoma), [NCIT:C5081](http://purl.obolibrary.org/obo/NCIT_C5081) (Stage II Nodular Sclerosis Classical Hodgkin Lymphoma), [NCIT:C5077](http://purl.obolibrary.org/obo/NCIT_C5077) (Stage II Mixed Cellularity Classical Hodgkin Lymphoma), [NCIT:C5067](http://purl.obolibrary.org/obo/NCIT_C5067) (Stage II Lymphocyte-Depleted Classical Hodgkin Lymphoma), [NCIT:C9033](http://purl.obolibrary.org/obo/NCIT_C9033) (Stage II Adult Hodgkin Lymphoma), [NCIT:C8055](http://purl.obolibrary.org/obo/NCIT_C8055) (Stage II Childhood Hodgkin Lymphoma), 

**Class expressions from DL-Learner:**

- [NCIT:C28054](http://purl.obolibrary.org/obo/NCIT_C28054) (Stage II) 54.17%
- Thing 52.77%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) 39.52%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39957](http://purl.obolibrary.org/obo/NCIT_C39957) (Epididymal Adenocarcinoma))) 39.52%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39956](http://purl.obolibrary.org/obo/NCIT_C39956) (Rete Testis Adenoma))) 39.52%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C3994](http://purl.obolibrary.org/obo/NCIT_C3994) (Stage IV Colon Cancer AJCC v6))) 39.52%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C3993](http://purl.obolibrary.org/obo/NCIT_C3993) (Stage II Colon Cancer AJCC v6))) 39.52%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39914](http://purl.obolibrary.org/obo/NCIT_C39914) (Gain of Chromosome 12p))) 39.52%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C3991](http://purl.obolibrary.org/obo/NCIT_C3991) (Thrombocytopenia Due to Immune Destruction))) 39.52%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39909](http://purl.obolibrary.org/obo/NCIT_C39909) (Gain of Chromosome 18q))) 39.52%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39907](http://purl.obolibrary.org/obo/NCIT_C39907) (Seminal Vesicle Cystadenoma))) 39.52%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39906](http://purl.obolibrary.org/obo/NCIT_C39906) (Seminal Vesicle Adenocarcinoma))) 39.52%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39905](http://purl.obolibrary.org/obo/NCIT_C39905) (Prostate Stromal Proliferation of Uncertain Malignant Potential))) 39.52%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39903](http://purl.obolibrary.org/obo/NCIT_C39903) (Prostate Adenocarcinoma with Focal Neuroendocrine Differentiation))) 39.52%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39902](http://purl.obolibrary.org/obo/NCIT_C39902) (Prostate Basal Cell Carcinoma))) 39.52%


